158 related articles for article (PubMed ID: 22348067)
1. Allele-specific deletions in mouse tumors identify Fbxw7 as germline modifier of tumor susceptibility.
Perez-Losada J; Wu D; DelRosario R; Balmain A; Mao JH
PLoS One; 2012; 7(2):e31301. PubMed ID: 22348067
[TBL] [Abstract][Full Text] [Related]
2. Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas.
Jen KY; Song IY; Banta KL; Wu D; Mao JH; Balmain A
Blood; 2012 Jan; 119(3):805-9. PubMed ID: 22117044
[TBL] [Abstract][Full Text] [Related]
3. Expression profiling reveals transcriptional regulation by Fbxw7/mTOR pathway in radiation-induced mouse thymic lymphomas.
Snijders AM; Liu Y; Su L; Huang Y; Mao JH
Oncotarget; 2015 Dec; 6(42):44794-805. PubMed ID: 26575021
[TBL] [Abstract][Full Text] [Related]
4. Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice.
Nagase H; Mao JH; Balmain A
Cancer Res; 2003 Aug; 63(16):4849-53. PubMed ID: 12941805
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of allele-specific somatic changes of genome-wide association study susceptibility alleles in human colorectal cancers.
Gerber MM; Hampel H; Schulz NP; Fernandez S; Wei L; Zhou XP; de la Chapelle A; Ewart Toland A
PLoS One; 2012; 7(5):e37672. PubMed ID: 22629442
[TBL] [Abstract][Full Text] [Related]
6. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.
Mao JH; Perez-Losada J; Wu D; Delrosario R; Tsunematsu R; Nakayama KI; Brown K; Bryson S; Balmain A
Nature; 2004 Dec; 432(7018):775-9. PubMed ID: 15592418
[TBL] [Abstract][Full Text] [Related]
7. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
8. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
[TBL] [Abstract][Full Text] [Related]
9. FBXW7 mutations typically found in human cancers are distinct from null alleles and disrupt lung development.
Davis H; Lewis A; Spencer-Dene B; Tateossian H; Stamp G; Behrens A; Tomlinson I
J Pathol; 2011 Jun; 224(2):180-9. PubMed ID: 21503901
[TBL] [Abstract][Full Text] [Related]
10. Convergence of congenic mapping and allele-specific alterations in tumors for the resolution of the Skts1 skin tumor susceptibility locus.
de Koning JP; Wakabayashi Y; Nagase H; Mao JH; Balmain A
Oncogene; 2007 Jun; 26(28):4171-8. PubMed ID: 17311004
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
Breast Cancer Res; 2010; 12(6):R105. PubMed ID: 21122106
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility.
Mao JH; Saunier EF; de Koning JP; McKinnon MM; Higgins MN; Nicklas K; Yang HT; Balmain A; Akhurst RJ
Proc Natl Acad Sci U S A; 2006 May; 103(21):8125-30. PubMed ID: 16702541
[TBL] [Abstract][Full Text] [Related]
13. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis.
Onoyama I; Tsunematsu R; Matsumoto A; Kimura T; de Alborán IM; Nakayama K; Nakayama KI
J Exp Med; 2007 Nov; 204(12):2875-88. PubMed ID: 17984302
[TBL] [Abstract][Full Text] [Related]
14. Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development.
Liu Y; Huang Y; Wang Z; Huang Y; Li X; Louie A; Wei G; Mao JH
Aging (Albany NY); 2013 Feb; 5(2):111-9. PubMed ID: 23454868
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor gene FBXW7 is disrupted by a constitutional t(3;4)(q21;q31) in a patient with renal cell cancer.
Kuiper RP; Vreede L; Venkatachalam R; Ricketts C; Kamping E; Verwiel E; Govaerts L; Debiec-Rychter M; Lerut E; van Erp F; Hoogerbrugge N; van Kempen L; Schoenmakers EF; Bonne A; Maher ER; Geurts van Kessel A
Cancer Genet Cytogenet; 2009 Dec; 195(2):105-11. PubMed ID: 19963109
[TBL] [Abstract][Full Text] [Related]
16. Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway.
Perez-Losada J; Mao JH; Balmain A
Cancer Res; 2005 Aug; 65(15):6488-92. PubMed ID: 16061623
[TBL] [Abstract][Full Text] [Related]
17. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
[TBL] [Abstract][Full Text] [Related]
18. Multiple novel alternative splicing forms of FBXW7α have a translational modulatory function and show specific alteration in human cancer.
Liu Y; Ren S; Castellanos-Martin A; Perez-Losada J; Kwon YW; Huang Y; Wang Z; Abad M; Cruz-Hernandez JJ; Rodriguez CA; Sun Y; Mao JH
PLoS One; 2012; 7(11):e49453. PubMed ID: 23166673
[TBL] [Abstract][Full Text] [Related]
19. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability.
Kemp Z; Rowan A; Chambers W; Wortham N; Halford S; Sieber O; Mortensen N; von Herbay A; Gunther T; Ilyas M; Tomlinson I
Cancer Res; 2005 Dec; 65(24):11361-6. PubMed ID: 16357143
[TBL] [Abstract][Full Text] [Related]
20. Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas.
Buckley AR; Ideker T; Carter H; Harismendy O; Schork NJ
Genome Med; 2018 Sep; 10(1):69. PubMed ID: 30217226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
